Despite a net loss, Moderna Inc (MRNA) showcases resilience with significant cost cuts, new FDA approvals, and a robust cash ...

Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, ...

HHS Secretary Robert F. Kennedy Jr. has upended the way Covid vaccines are approved and for whom they’re recommended, ...

Moderna is counting on new mRNA products such as its experimental COVID-flu combo shot to offset slumping COVID vaccine sales ...

The reduction of people getting COVID vaccines is hitting Moderna. It plans to cut some of its workforce by the end of the year.

US pharmaceutical giant Pfizer and German firm BioNTech lost Friday a court appeal in the latest step of a multi-million-pound battle against US rival Moderna over the Covid-19 vaccine.

Moderna has announced that it plans to cut down 10% of its workforce by the end of the year. CEO Stephane Bancel said in a ...

Moderna's (NASDAQ:MRNA) quarter was okay on the numbers, but the stock slid because the company pulled back its full-year ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Discover the latest Wall Street trends: market declines, Q2 earnings highlights, and key stock moves from Tesla, Meta, Microsoft, and more.

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...